These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 9486676

  • 1. Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma.
    Vonderheid EC, Zhang Q, Lessin SR, Polansky M, Abrams JT, Bigler RD, Wasik MA.
    J Am Acad Dermatol; 1998 Feb; 38(2 Pt 1):207-20. PubMed ID: 9486676
    [Abstract] [Full Text] [Related]

  • 2. Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications.
    Wasik MA, Vonderheid EC, Bigler RD, Marti R, Lessin SR, Polansky M, Kadin ME.
    Arch Dermatol; 1996 Jan; 132(1):42-7. PubMed ID: 8546482
    [Abstract] [Full Text] [Related]

  • 3. Increased frequency of skin-infiltrating FoxP3+ regulatory T cells as a diagnostic indicator of severe atopic dermatitis from cutaneous T cell lymphoma.
    Hanafusa T, Matsui S, Murota H, Tani M, Igawa K, Katayama I.
    Clin Exp Immunol; 2013 Jun; 172(3):507-12. PubMed ID: 23600840
    [Abstract] [Full Text] [Related]

  • 4. Extracorporeal photochemotherapy in patients with cutaneous T-cell lymphoma: is clinical response predictable?
    Rao V, Ryggen K, Aarhaug M, Dai HY, Jørstad S, Moen T.
    J Eur Acad Dermatol Venereol; 2006 Oct; 20(9):1100-7. PubMed ID: 16987266
    [Abstract] [Full Text] [Related]

  • 5. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma.
    Vidulich KA, Talpur R, Bassett RL, Duvic M.
    Int J Dermatol; 2009 Mar; 48(3):243-52. PubMed ID: 19261011
    [Abstract] [Full Text] [Related]

  • 6. [Clinical significance of serum soluble interleukin-2 receptor level in patients with non-Hodgkin's lymphoma].
    Shimomura Y, Tsurumi H, Sawada M, Yamada T, Hara T, Fukuno K, Goto H, Moriwaki H.
    Rinsho Ketsueki; 1999 Aug; 40(8):639-45. PubMed ID: 10496038
    [Abstract] [Full Text] [Related]

  • 7. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C.
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [Abstract] [Full Text] [Related]

  • 8. Soluble interleukin-2 receptors inhibit interleukin 2-dependent proliferation and cytotoxicity: explanation for diminished natural killer cell activity in cutaneous T-cell lymphomas in vivo?
    Dummer R, Posseckert G, Nestle F, Witzgall R, Burger M, Becker JC, Schäfer E, Wiede J, Sebald W, Burg G.
    J Invest Dermatol; 1992 Jan; 98(1):50-4. PubMed ID: 1728640
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia.
    Kamihira S, Atogami S, Sohda H, Momita S, Yamada Y, Tomonaga M.
    Cancer; 1994 Jun 01; 73(11):2753-8. PubMed ID: 8194016
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Measurement of the concentration of serum soluble interleukin-2 receptor alpha chain in dogs with lymphoma.
    Mizutani N, Goto-Koshino Y, Kurata K, Fujiwara-Igarashi A, Sakaguchi M, Asada M, Ohno K, Tsujimoto H.
    Vet Immunol Immunopathol; 2020 Jul 01; 225():110054. PubMed ID: 32434088
    [Abstract] [Full Text] [Related]

  • 15. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.
    Goto H, Tsurumi H, Takemura M, Ino-Shimomura Y, Kasahara S, Sawada M, Yamada T, Hara T, Fukuno K, Goto N, Okuno M, Takami T, Seishima M, Moriwaki H.
    J Cancer Res Clin Oncol; 2005 Feb 01; 131(2):73-9. PubMed ID: 15503137
    [Abstract] [Full Text] [Related]

  • 16. The serum levels of soluble interleukin-2 receptor alpha and lactate dehydrogenase but not of B2-microglobulin correlate with selected clinico-pathological prognostic factors and response to therapy in childhood soft tissue sarcomas.
    Bien E, Rapala M, Krawczyk M, Balcerska A.
    J Cancer Res Clin Oncol; 2010 Feb 01; 136(2):293-305. PubMed ID: 19693535
    [Abstract] [Full Text] [Related]

  • 17. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution.
    Gottlieb SL, Wolfe JT, Fox FE, DeNardo BJ, Macey WH, Bromley PG, Lessin SR, Rook AH.
    J Am Acad Dermatol; 1996 Dec 01; 35(6):946-57. PubMed ID: 8959954
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of serum sIL-2R and LDH levels in patients with intravascular large B-cell lymphoma and patients with advanced stage diffuse large B-cell lymphoma.
    Hirami Y, Nishimura MF, Urata T, Morimoto M, Maekawa Y, Yoshino T, Nishimura Y, Sato Y.
    J Clin Exp Hematop; 2023 Mar 28; 63(1):25-31. PubMed ID: 36843068
    [Abstract] [Full Text] [Related]

  • 20. Treatment of cutaneous T cell lymphoma: current status and future directions.
    Apisarnthanarax N, Talpur R, Duvic M.
    Am J Clin Dermatol; 2002 Mar 28; 3(3):193-215. PubMed ID: 11978140
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.